
Oncurious NV is an emerging biotech company focusing on the development of the next oncology treatments #NextGenImmunoOncology #PediatricBrainCancer
Leuven, Belgium
Joined June 2013
- Tweets72
- Following73
- Followers219
- Likes46
Oncurious retweeted
. @Oxurion publishes results from Phase 1 trial of THR-687 for #DME treatment; is now recruiting patients for Phase 2 clinical study buff.ly/3AMjs9c
Oncurious retweeted
Published papers by @Oxurion in the Journal of Pharmacokinetics and Pharmacodynamics describe desirable #clinicalstudy profiles of THR-149 and THR-687 for #retinalvascular disorders:
oxurion.com/content/oxurion-…
#lifesciences #biopharma #publishing #opthamology
Oxurion NV - Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal globenewswire.com/news-relea…
Oncurious retweeted
As we close out #BrainTumorAwarenessMonth, we hope you will join us & #GiveHopeAName by making a donation to @PBTF in honor of every child who has battled a brain tumor.
Donate today: buff.ly/2ToF7UG
#CareCureThrive #BrainCancerAwareness #GoGray #BrainTumorAwareness
Very excited and proud to present encouraging data from a Phase 1 Phase 1 Dose Escalation Study of #TB403 in Paediatric Subjects with Relapsed or Refractory Medulloblastoma https://teapawt.net/t.co/BuwRISTrH9 #AACR21 #cancerresearch @Oncurious @NMTRC @VIBLifeSciences @CarmelietLab
Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in Paediatric Subjects with Relapsed or Refractory Medulloblastoma Presented at the American Association for Cancer Research 2021 Annual Meeting globenewswire.com/news-relea…
2
Excited to attend and present preclinical and clinical data at the AACR 2021 Annual Meeting! thttps://bit.ly/2PGc2md #ccr8 #immunotherapy #tb403 #medulloblastoma
Journal of ImmunoTherapy for Cancer published research findings by @Oncurious @VIBLifeSciences highlighting efficacy and safety of targeting CCR8 for depletion of tumor-promoting ti-Tregs in combo with anti-PD-1 therapy ap.lc/k3RWw #immunotherapy #cancer #CCR8 #leuven
We've got news from our I-O portfolio! @Oncurious @VIBLifeSciences Announcing First Preclinical Proof of Concept in Proprietary CCR8 Treg Program. Follow the link to our updated website: https://teapawt.net/t.co/wcQvCcsEPa
Moreover, bij @Oncurious zijn we #ontrack om rond mid 2020 een eerste preklinische PoC voor te stellen We werken aan immuno-oncotherapieën van de volgende generatie voor een breed spectrum van kankertypes. @Oxurion is 85% eigenaar, @VIBLifeSciences 15% #partnersinscience
This Post is from an account that no longer exists. Learn more
Congrats to the @Oxurion and @Bicycle_tx team ! 👏
This Post is from an account that no longer exists. Learn more
5
@ONCURIOUS NV Receives $1 M Grant from VLAIO to Progress Pipeline of Next Generation Cancer Immunotherapies https://teapawt.net/t.co/D96ofZftcz #nextlevel
Oncurious retweeted
Today is #WorldCancerDay 🍀. At the CCB we focus every day on #Cancer research, raise #Awareness about it and make it a global priority to #improve early #diagnosis & #discover effective #treatments for all patients.
Oncurious retweeted
Our featured story this week! Role of Glutamine Synthetase in Angiogenesis beyond Glutamine Synthesis @LeuvenU @harvardmed @nature @CarmelietLab ow.ly/Ys0z30lMbCc
Congratulations @ThromboGenics ! teapawt.net/ThromboGenics/status/9…
1
5
Congratulations to Prof Peter Carmeliet @vib_ccb @VIBLifeSciences ! Well deserved! teapawt.net/VIBLifeSciences/status…
3
Hij vertrok vanuit #Leuven om elke dag 76 kilometer te lopen. Aangekomen! Van harte gefeliciteerd @SwinnenJohan ! goo.gl/7FLMZ1
Congratulations to the @ThromboGenics and @NovartisPharma team! teapawt.net/ThromboGenics/status/9…
2
Oncurious retweeted
Oncurious to buy VIB’s Immune-Oncology portfolio ow.ly/pBey30eVEjA














